New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 28, 2021
- Accepted in final form June 24, 2021
- First Published October 19, 2021.
Author Disclosures
- Yukio Takeshita, MD, PhD* (takeshy{at}yamaguchi-u.ac.jp),
- Susumu Fujikawa, MD* (smfujika{at}yamaguchi-u.ac.jp),
- Kenichi Serizawa, PhD (serizawakni{at}chugai-pharm.co.jp),
- Miwako Fujisawa, MD (fuji0418{at}yamaguchi-u.ac.jp),
- Kinya Matsuo, MD (matsuok{at}yamaguchi-u.ac.jp),
- Joe Nemoto, MD (nemoto{at}yamaguchi-u.ac.jp),
- Fumitaka Shimizu, MD, PhD (fshimizu{at}yamaguchi-u.ac.jp),
- Yasuteru Sano, MD, PhD (yasuteru{at}yamaguchi-u.ac.jp),
- Haruna Tomizawa-Shinohara, PhD (shinohara.haruna89{at}chugai-pharm.co.jp),
- Shota Miyake (miyake.shota34{at}chugai-pharm.co.jp),
- Richard M. Ransohoff, MD, PhD (rransohoff{at}thirdrockventures.com) and
- Takashi Kanda, MD, PhD
- Yukio Takeshita, MD, PhD* (takeshy{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Susumu Fujikawa, MD* (smfujika{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kenichi Serizawa, PhD (serizawakni{at}chugai-pharm.co.jp),
NONE
NONE
NONE
NONE
(1) Filing a patent application(PCT/JP2020/005965; (Inhibitory effect of anti-IL-6 receptor antibody on BBB dysfunction)
NONE
(1)Chugai Pharmaceutical Co., Ltd., general employee, 14 years
NONE
NONE
NONE
NONE
I am employee of Chugai Pharmaceutical Co., Ltd. So our research was funded from Chugai Pharmaceutical Co., Ltd. departmental resources.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Miwako Fujisawa, MD (fuji0418{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kinya Matsuo, MD (matsuok{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joe Nemoto, MD (nemoto{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fumitaka Shimizu, MD, PhD (fshimizu{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, postdoctoral scientist, 1 years 10 month(2014.11- 2016.8)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yasuteru Sano, MD, PhD (yasuteru{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Haruna Tomizawa-Shinohara, PhD (shinohara.haruna89{at}chugai-pharm.co.jp),
NONE
NONE
NONE
NONE
NONE
NONE
(1)Chugai Pharmaceutical Co., LTD., general employee. 6 years
NONE
NONE
NONE
NONE
I am employee of Chugai Pharmaceutical Co., LTD. So our research was funded from Chugai Pharmaceutical Co., LTD. departmental resource.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shota Miyake (miyake.shota34{at}chugai-pharm.co.jp),
NONE
NONE
NONE
NONE
NONE
NONE
(1) Chugai Pharmaceutical co., Ltd., general employee, 2 years
NONE
NONE
NONE
NONE
I am employee of Chugai Pharmaceutical Co., Ltd. So our research was funded from Chugai Pharmaceutical Co., Ltd. departmental resources.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Richard M. Ransohoff, MD, PhD (rransohoff{at}thirdrockventures.com) and
NONE
NONE
NONE
NONE
NONE
NONE
Employed at present by Third Rock Ventures as Venture Partner. This work is unrelated to my employment at Third Rock Ventures.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Chemocentryx, exercise and sell stock options Stock/Stock Options, Medical Equipment & Materials: Third Rock Ventures, Fund V and related portfolio companies
NONE
NONE
NONE
NONE
NONE
- Takashi Kanda, MD, PhD
(1) CSL Behring (2) Chugai Paharmaceutical Co.
NONE
(1) Novartis Pharma Co, speaker honararia (2) Otsuka Pharmaceutical, speaker honararia (3) Ayumi Pharmaceutical, speaker honararia (4) Japan Blood, speaker honararia (5) Takeda Pharmacuetical Co., speaker honararia (6) Kyowa-Kirin Pharmaceutical Co., speaker honararia (7) Dainipponsumitomo Pharmaceutical Co., speaker honararia (8) Tanabe Mitsubishi Pharmaceutical Co., speaker honararia (9) CSL Behring,, speaker honararia (10) Janssen Pahrmaceutical Co., speaker honararia (11) Teijin Pharm., speaker honararia (12) Biogen Japan, speaker honararia (13) Eosai Pharmaceutical, speaker honararia (14) Alexion Pharm., speaker honararia (15) Glaxo Smith Klein, , speaker honararia (16) Ono Pharmaceutical Co., speaker honararia
(1) Clinical and Experimental Neuroimmunology Editor-in- Chief 2010-2018 (2) Neuropathology, Editorial Advisory Board Member 2009- (3) Brain and Nerve Editor-in-Chief 2018- (4) Peripheral Nerve, Editor-in-Chief, 2017-2021 (5) Fluids and Barriers of the CNS, Editor 2014-
(1) in vitro model of blood-brain barrier
NONE
NONE
(1) Teijin pharmaceutical Co.
NONE
NONE
NONE
(1) Novartis Pharm. (2) Daiichi-Sankyo Co. (3) Asteras Co.
(1) Contract Grant Sponsor: Japan Society for the Promotion of Science - Tokyo Contract Grant Number: 25293203, 26670443, 17H04197
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Clinical Neuroscience (Y.T., S.F., M.F., K.M., J.N., F.S., Y.S., T.K.), Yamaguchi University Graduate School of Medicine; Kenichi Serizawa (K.S., H.T.-S., S.M.), Haruna Tomizawa-Shinohara and Shota Miyake, Product Research Department, Chugai Pharmaceutical Co., Ltd, Kanagawa, Japan; and Richard M Ransohoff (R.M.R.), Third Rock Ventures, Boston, MA.
- Correspondence
Dr. Kanda tkanda{at}yamaguchi-u.ac.jp
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.